Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles W Locuson

Showing results (21-30 of 37) with videos related to

Pageof 4
Sort By:
Chemical Research in Toxicology|December 19, 2006
Inhibition of cytochrome P450 3A4 by a pyrimidineimidazole: Evidence for complex heme interactionsJ Matthew Hutzler, Roger J Melton, Jeanne M Rumsey, et al.
American Journal of Veterinary Research|February 25, 2021
Multiple-dose pharmacokinetics and opioid effects of a novel analgesic with a deterrent to human opioid abuse (methadone-fluconazole-naltrexone) after oral administration in dogsButch KuKanich, Kate KuKanich, Charles W Locuson, et al.
Drug Metabolism Letters|March 20, 2012
A non-acidic sulfaphenazole analog demonstrating high intrinsic clearance and selectivity by canine CYP2C21Charles W Locuson, Josh F Alfaro, Matthew J Zaya, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|December 17, 2009
Current cytochrome P450 phenotyping methods applied to metabolic drug-drug interaction prediction in dogsBeth Miskimins Mills, Matthew J Zaya, Rodney R Walters, et al.
Molecular Pharmacology|June 16, 2005
CYP2C9 genotype-dependent effects on in vitro drug-drug interactions: switching of benzbromarone effect from inhibition to activation in the CYP2C9.3 variantMatthew A Hummel, Charles W Locuson, Peter M Gannett, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|August 13, 2015
A Screen of Approved Drugs Identifies the Androgen Receptor Antagonist Flutamide and Its Pharmacologically Active Metabolite 2-Hydroxy-Flutamide as Heterotropic Activators of Cytochrome P450 3A In Vitro and In VivoAnna L Blobaum, Frank W Byers, Thomas M Bridges, et al.
Bioorganic & Medicinal Chemistry Letters|March 25, 2015
Synthesis and structure-activity relationships of a series of 4-methoxy-3-(piperidin-4-yl)oxy benzamides as novel inhibitors of the presynaptic choline transporterSean R Bollinger, Darren W Engers, Elizabeth A Ennis, et al.
Journal of the American Chemical Society|June 29, 2006
Preparation, characterization, and substrate metabolism of gold-immobilized cytochrome P450 2C9Peter M Gannett, Jarod Kabulski, Felio A Perez, et al.
Bioorganic & Medicinal Chemistry Letters|May 20, 2015
Progress towards small molecule menin-mixed lineage leukemia (MLL) interaction inhibitors with in vivo utilityTimothy Senter, Rocco D Gogliotti, Changho Han, et al.
ACS Medicinal Chemistry Letters|September 16, 2014
Discovery and Characterization of ML398, a Potent and Selective Antagonist of the D4 Receptor with in Vivo ActivityCynthia B Berry, Michael Bubser, Carrie K Jones, et al.
Pageof 4

Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
Chemical Research in Toxicology|December 19, 2006
Inhibition of cytochrome P450 3A4 by a pyrimidineimidazole: Evidence for complex heme interactionsJ Matthew Hutzler, Roger J Melton, Jeanne M Rumsey, et al.
American Journal of Veterinary Research|February 25, 2021
Multiple-dose pharmacokinetics and opioid effects of a novel analgesic with a deterrent to human opioid abuse (methadone-fluconazole-naltrexone) after oral administration in dogsButch KuKanich, Kate KuKanich, Charles W Locuson, et al.
Drug Metabolism Letters|March 20, 2012
A non-acidic sulfaphenazole analog demonstrating high intrinsic clearance and selectivity by canine CYP2C21Charles W Locuson, Josh F Alfaro, Matthew J Zaya, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|December 17, 2009
Current cytochrome P450 phenotyping methods applied to metabolic drug-drug interaction prediction in dogsBeth Miskimins Mills, Matthew J Zaya, Rodney R Walters, et al.
Molecular Pharmacology|June 16, 2005
CYP2C9 genotype-dependent effects on in vitro drug-drug interactions: switching of benzbromarone effect from inhibition to activation in the CYP2C9.3 variantMatthew A Hummel, Charles W Locuson, Peter M Gannett, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|August 13, 2015
A Screen of Approved Drugs Identifies the Androgen Receptor Antagonist Flutamide and Its Pharmacologically Active Metabolite 2-Hydroxy-Flutamide as Heterotropic Activators of Cytochrome P450 3A In Vitro and In VivoAnna L Blobaum, Frank W Byers, Thomas M Bridges, et al.
Bioorganic & Medicinal Chemistry Letters|March 25, 2015
Synthesis and structure-activity relationships of a series of 4-methoxy-3-(piperidin-4-yl)oxy benzamides as novel inhibitors of the presynaptic choline transporterSean R Bollinger, Darren W Engers, Elizabeth A Ennis, et al.
Journal of the American Chemical Society|June 29, 2006
Preparation, characterization, and substrate metabolism of gold-immobilized cytochrome P450 2C9Peter M Gannett, Jarod Kabulski, Felio A Perez, et al.
Bioorganic & Medicinal Chemistry Letters|May 20, 2015
Progress towards small molecule menin-mixed lineage leukemia (MLL) interaction inhibitors with in vivo utilityTimothy Senter, Rocco D Gogliotti, Changho Han, et al.
ACS Medicinal Chemistry Letters|September 16, 2014
Discovery and Characterization of ML398, a Potent and Selective Antagonist of the D4 Receptor with in Vivo ActivityCynthia B Berry, Michael Bubser, Carrie K Jones, et al.
Pageof 4